Effects of angiotensin converting enzyme inhibitor: ramipril on different biochemical parameters in essential hypertensive patients

Salve, Pratibha S.; Khanwelkar, Chitra C.; Salve, Preeti S.; Thorat, Vandana M.; Matule, Somnath M.

doi:10.18203/2320-6012.ijrms20161801

Cited by 1 publication

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In group B (Ramipril), the fall was 3.10 mg/dL (~3%) from initial baseline of 104.77±11.58 mg/dL (p<0.001), whereas Salve PS et al reported a mean fall of ~3 mg/dL (3.7%) from the initial baseline of 79.37±8.34 mg/dL (p<0.01) which was almost equivalent to that observed in the present study. 1 Fasting plasma insulin (Table 5) In group A, after 12 weeks of treatment, mean fall in FPI was 1.04 µU/ml (~11%) from baseline value of 9.51±1.33 µU/ml (p<0.001) whereas Miura et al10 after 12 weeks of study reported a 2.1 µU/ml fall in FPI, from the initial baseline of 10.7±3.8 (p<0.01).…”

Section: Homa-ir Valuementioning

confidence: 92%

“…Hypertension is considered as a metabolic syndrome which affects many systems of the body and alters various biochemical parameters. 1 It is defined as a systolic blood pressure (SBP) of 140 mm Hg or more, or a diastolic blood pressure (DBP) of 90 mm Hg or more or taking antihypertensive medication. 2 Hypertension is responsible for at least 45% of deaths due to heart disease and 51% of deaths due to stroke.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The effect of Ramipril and Telmisartan on blood pressure and insulin resistance in hypertensive patients

Watts

Singh

Rai

2019

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

Background: Angiotensin converting enzyme (ACE) inhibitors and Angiotensin II Receptor Blockers (ARBs) have become keystones of therapy for hypertension but there are very few studies where they have been compared with each other. This study attempted to compare the effect of Ramipril and Telmisartan on Blood Pressure and Insulin Resistance in Hypertensive patients (JNC 8).Methods: An open label, randomized, prospective and comparative study of twelve- week duration was conducted on 60 patients of hypertension (JNC-8), with the collaboration of Department of Pharmacology and Department of Medicine, Government Medical College, Amritsar. Group A and B were given Telmisartan 40mg and Ramipril 2.5 mg OD respectively. Blood Pressure was recorded on every visit, whereas, fasting plasma insulin and HOMA-IR values were recorded at the baseline and at the end of the study. Fasting blood sugar was done at 0, 4 and 12 weeks.Results: At the end of 12 weeks, a significant reduction in Systolic/Diastolic blood pressure was observed in group A with a drop of ~14/9 mmHg (p<0.001) and in group B too, the fall of ~11.6/7.2 mmHg was significant (p<0.001). However, in inter-group comparison only SBP difference was significant between two groups (p<0.05). Change in HOMA-IR value was also significant in both the groups (p<0.001). The inter-group difference for HOMA-IR between both the groups (A vs B) was also statistically significant (p<0.01).Conclusions: Telmisartan 40 mg OD was more effective than Ramipril 2.5 mg OD in controlling the SBP and improving Insulin resistance at the end of 12 weeks.

show abstract

Section: Homa-ir Valuementioning

confidence: 92%

Section: Introductionmentioning

confidence: 99%